Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $27.71.

CNTA has been the subject of a number of research analyst reports. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price for the company. Finally, Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th.

Insider Activity

In other news, insider Karen M. Anderson sold 6,471 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $109,101.06. Following the transaction, the insider now owns 54,322 shares of the company’s stock, valued at approximately $915,868.92. This represents a 10.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of the firm’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total value of $29,140.80. Following the completion of the transaction, the general counsel now directly owns 105,386 shares in the company, valued at $1,476,457.86. The trade was a 1.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 219,513 shares of company stock worth $3,576,685 in the last ninety days. Corporate insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $20,994,000. Franklin Resources Inc. raised its stake in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after buying an additional 924,027 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in shares of Centessa Pharmaceuticals by 26.2% in the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after buying an additional 710,936 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Down 1.5 %

Centessa Pharmaceuticals stock opened at $13.50 on Friday. The firm has a 50-day moving average price of $14.22 and a two-hundred day moving average price of $15.81. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -8.82 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. Sell-side analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.